The Inflation Reduction Act may disrupt a substantial amount of investment into finding new uses for already approved oncology drugs, researchers say.
The R&D investment made by the nearly dozen largest drug manufacturers totaled $104 billion last year.
Sanofi will be on the hook for additional payments if certain research, development and sales milestones are met by Insilico.
The consultancy’s annual report on R&D investment returns revealed a COVID-related bump in R&D investment returns.
The Number One agency on our Agency 100 list is collaborating with outside organizations to develop digital tools to help combat COVID-19.
Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.
As the country contends with the spread of the coronavirus, China’s next decade will see the evolution of health policy and regulation.
Several candidates relegated to the R&D graveyard re-emerged from their tombs this year and now headline the pharma developmental slate for 2020.
IQVIA examined the research and development landscape of 2018.
The holding company health unit will work with the university on its initiatives around the world.
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: